How many times should I follow up with a CTO (after a demo)?

If a mutual offered the intro, send it while their permission is fresh. Same day with the recap. A value bump 3 days later if they went quiet. After that, send a breakup note and archive it. A CTO who wants it will answer a clean close more often than a fifth bump.

How do I introduce myself without sounding stiff?

Use one sentence for who you help and one sentence for why now. Skip the origin story. If a mutual is involved, put their name near the top so the email has a human reason to exist. Name the stall they care about, offer one small next step, and stop before the thread feels like a sequence.

Should I include a recording in the demo follow-up?

If you recorded it and they agreed, yes, plus timestamps for the two parts they cared about. A raw 40-minute link with no map is homework. Add the three bullets they'd need to brief a colleague. Name the stall they care about, offer one small next step, and stop before the thread feels like a sequence.

Is it okay to send this introduction on LinkedIn instead of email?

Yes if this CTO is actually active there and the thread isn't about long attachments. Keep the LinkedIn version even shorter. Don't paste the full email. One context line and one question is plenty. Name the stall they care about, offer one small next step, and stop before the thread feels like a sequence.

What should I never say in a Pharmaceuticals introduction?

Don't use consumer-startup slang. It's a credibility leak. Calling it 'AI-powered' with no description of the system. Don't send a 19-page deck that relitigates features they skipped. Those three mistakes show up constantly in Pharmaceuticals inboxes and they all read as "this was templated."

Pharmaceuticals · CTO · After Demo

Introduction for Pharmaceuticals CTO: After Demo

A introduction email for a Pharmaceuticals CTO (after a demo) is a short message that reopens the thread without making them do extra work. An introduction email explains who you are, why this person should care, and what a good next step looks like, without making them do the homework. In this setting, that means speaking to follow-up that ignores

Last updated: 2026-09-02 · Reviewed by: Sales Email Template editors

We write templates the way we wrote emails on quota: short, specific, and easy to forward. When we cite research below, it is because the number changes how a buyer reads your note, not to pad the page.

Sources: HubSpot sales email benchmarks; Gong follow-up research

Why does this introduction work for a Pharmaceuticals CTO?

Make it easy to decline.
Speaks to follow-up that ignores MLR, off-label risk, and the fact that 'just a quick claim' isn't quick instead of a generic "value prop."
Fits how a CTO actually reads: 90 words is plenty if the substance is real. Don't pad.
Replay the two moments they leaned in, and the one concern they named.
Lead with the overlap, not your résumé.

When should I send this to a Pharmaceuticals CTO?

If a mutual offered the intro, send it while their permission is fresh. Same day with the recap. A value bump 3 days later if they went quiet. For this combo, treat "Same day, then 3 days if silent" as the default, then adjust around launch calendars and review boards set speed. you don't. If you're emailing a CTO, 90 words is plenty if the substance is real. Don't pad.

What this CTO actually cares about

A CTO in Pharmaceuticals is protecting reliability, security, and engineering time. They look for architecture, failure modes, and whether you'll create toil for their team. Fluff is a ranking signal that you don't know the work. The hook that earns a look is an incident class, a security gap, or a cost line they already hate. The ask should stay at this size: a technical working session or a written teardown, not a 'vision call'. Delete trigger: Calling it 'AI-powered' with no description of the system. an incident class, a security gap, or a cost line they already hate

How Pharmaceuticals changes the note

Pharmaceuticals buyers are commercial, medical, and ops leads who work under review boards and long timelines. Don't invent clinical claims. Don't treat HCPs like a funnel. If you don't know the rules, your email is a liability. A credible proof point in this vertical sounds like: cut review cycles on a leave-behind by catching claims issues before legal saw the tenth draft. Watch the language. Words that land here include MLR, label, access, HCP, congress, promotional review. Launch calendars and review boards set speed. You don't. Words that work: MLR, label, access, HCP, congress, promotional review.

How should I customize this template before I send it?

Replace the pain line with an agency waiting on MLR while the sales team keeps asking 'is it approved yet'.
Keep the tone precise.
Don't attach your pitch deck to an intro.
Time it for Same day, then 3 days if silent. Same day with the recap. A value bump 3 days later if they went quiet.
Don't use consumer-startup slang. It's a credibility leak.

What mistakes should I avoid with this after demo note?

Giant bios make intros feel like homework.
Don't send a 19-page deck that relitigates features they skipped.
Don't use consumer-startup slang. It's a credibility leak.
Calling it 'AI-powered' with no description of the system.

How does this after demo scenario compare?

Dimension	For this template
Best send window	Same day, then 3 days if silent
Ideal length	90 words is plenty if the substance is real. Don't pad.
Primary ask	a technical working session or a written teardown, not a 'vision call'
Industry metric to cite	time through MLR, access, and compliant engagement rates
Tone	Precise. No slogans. It's fine to be a little dry.
Unlike after meeting	They have product context now. Speak to what they saw, not to a generic intro.
Unlike after proposal	Pricing may not be on paper yet. Don't jump to 'ready to sign.'

What should I copy and send?

Copy-ready template

Subject

[Mutual] suggested I reach out about [topic]

Body

Hi [First Name],

I'll keep this short so you can decide if a conversation is worth it.

In Pharmaceuticals, that usually shows up as follow-up that ignores MLR, off-label risk, and the fact that 'just a quick claim' isn't quick. Two reasons this might matter now: [trigger 1] and [trigger 2]. If I'm reading that wrong, tell me.

Replay the two moments they leaned in, and the one concern they named.

Open to a short intro chat, or should I leave this with [Mutual]?

Best,
[Your Name]
[Your Title]
[Your Company]

Questions people ask before they hit send

Name the situation and the business object, not your excitement. Something like "[Mutual] suggested I reach out about [topic]" outperforms "Just checking in" because a CTO can decide from the preview text whether it's worth opening. Keep it under 50 characters when you can.

Related templates

Want a custom draft instead? Try the email generator.